1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Dipeptidyl Peptidase

Dipeptidyl Peptidase

DPP

Dipeptidyl Peptidases are widely distributed exopeptidases that possess central role in proteolysis. The dipeptidyl peptidase family, including DPP-IV DPP7, DPP8, DPP9, fibroblast activation protein and others, cleave the peptide bond after the penultimate proline residue and are drug target rich.

DPP-IV (DPP4 or CD26) is a serine protease detected on several immune cells and on epithelial cells of various organs. Besides the membrane-bound enzyme, a catalytically active soluble form is detected in several body fluids. Both variants cleave off dipeptides from the N-termini of various chemokines, neuropeptides, and hormones. DPP IV plays a key role in immune-regulation, inflammation, oxidative stress, cell adhesion, and apoptosis by targeting different substrates. DPP IV inhibitors are commonly used as hypoglycemic agents.

DPP8 and DPP9 show DPPIV-like activity and share a very high-sequence similarity to each other. DPP8 and DPP9 are intracellular N-terminal dipeptidyl peptidases (preferentially postproline) associated with pathophysiological roles in immune response and cancer biology.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-117985A
    Evogliptin hydrochloride
    Inhibitor
    Evogliptin hydrochloride (DA-1229 hydrochloride) is an orally available DPP4 inhibitor with significant and durable hypoglycemic effects in mouse models. Evogliptin hydrochloride also inhibits the generation of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin hydrochloride can be used in the research of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
    Evogliptin hydrochloride
  • HY-10286A
    Dutogliptin tartrate
    Inhibitor
    Dutogliptin tartrate (PHX-1149) is an orally available, potent, and selective dipeptidyl peptidase-4 (DPP4) inhibitor for the treatment of type 2 diabetes mellitus.
    Dutogliptin tartrate
  • HY-14877A
    Anagliptin hydrochloride
    Inhibitor
    Anagliptin (SK-0403) hydrochloride is a highly selective, potent, orally active inhibitor of dipeptidyl peptidase 4 (DPP-4), with an IC50 of 3.8 nM, and less selective at DPP-8 and DDP-9 with IC50s of 68 nM and 60 nM, respectively.
    Anagliptin hydrochloride
  • HY-N10360
    Ellipyrone A
    Inhibitor
    Ellipyrone A, a γ-pyrone enclosed macrocyclic poyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.35 mM). Ellipyrone A also has anti-carbolytic property against α-glucosidase (IC50=0.74 mM) and α-amylase (IC50=0.59 mM).
    Ellipyrone A
  • HY-Z1764
    DPP-4-IN-18
    Inhibitor
    DPP-4-IN-18 (Sitagliptin impurity 3) (Compound 4) impurity 3 is a potent, selective and orally active DPP-4 inhibitor with an IC50 of 27 nM. DPP-4-IN-18 can effectively prevent DPP-4 from degrading glucagon-like peptide 1 (GLP-1), thereby increasing the level of active GLP-1. DPP-4-IN-18 can be used for the research of type 2 diabetes.
    DPP-4-IN-18
  • HY-13749C
    (S)-Sitagliptin phosphate
    Inhibitor
    (S)-Sitagliptin phosphate is the less active S-enantiomer of Sitagliptin phosphate. Sitagliptin phosphate (MK-0431 phosphate) is a potent inhibitor of DPP4 with an IC50 of 19 nM in Caco-2 cell extracts.
    (S)-Sitagliptin phosphate
  • HY-179348
    DPP9-IN-2
    Inhibitor
    DPP9-IN-2 is a selective, potent and orally active inhibitor of Dipeptidyl Peptidase 9 (DPP9 ) with an IC50 of 12.9 nM. DPP9-IN-2 shows a SI of 59 over DPP8, and shows no significant inhibitory activity against related peptidases including DPP2, DPP4, FAP, and PREP. DPP9-IN-2 can induce cancer cells pyroptosis and has weak synergistic anti-HIV-1 activity when combined with non-nucleoside reverse transcriptase inhibitor. DPP9-IN-2 can be used for the researches of cance rand infection.
    DPP9-IN-2
  • HY-14293
    NVP-DPP728 dihydrochloride
    Inhibitor
    NVP-DPP728 dihydrochloride is a potent, selective and orally active dipeptidyl peptidase IV (DPP-IV) inhibitor with a Ki of 11 nM. NVP-DPP728 dihydrochloride can be used for the research of diabetes mellitus.
    NVP-DPP728 dihydrochloride
  • HY-170572
    PB01
    Inhibitor
    PB01 is a DPP-4 inhibitor with an IC50 of 15.66 nM. It effectively inhibits high glucose-induced ROS production and mitochondrial superoxide formation while significantly reducing cellular DPP-4 expression. PB01 can also significantly lower blood glucose levels in diabetic mice. Additionally, PB01 demonstrates good safety, exhibiting almost no cytotoxicity at a concentration of 100 μM. PB01 holds potential for research in the field of diabetes.
    PB01
  • HY-163332
    MPO-IN-6
    Inhibitor
    MPO-IN-6 (compound ADC) is an electrophile with good antioxidant and anti-inflammatory properties. MPO-IN-6 is a myeloperoxidase (MPO), dipeptidyl peptidase-4 (DPP-4), and α-glucosidase (α-GD) inhibitor with IC50s of 10 μM, 31.02 μM, and 46.05 μM, respectively. MPO-IN-6 is a potential cardiovascular preventive agent.
    MPO-IN-6
  • HY-153522
    ZY15557
    Inhibitor
    ZY15557 is a novel, competitive, long acting, orally active DPP-4 inhibitor, with a Ki of 5.53 nM. ZY15557 inhibits plasma DPP-4 activity. ZY15557 can be used in the research of type 2 diabetes.
    ZY15557
  • HY-N10362
    Ellipyrone B
    Inhibitor
    Ellipyrone B, an antihyperglycemic γ-pyrone enclosed macrocyclic polyketide, shows inhibition potential against dipeptidyl peptidase-4 (IC50=0.48 mM).
    Ellipyrone B
  • HY-169724
    RBx-0597
    Inhibitor
    RBx-0597 is a potent and selective DPP-IV inhibitor, demonstrating IC50 values of 32, 31, and 39 nM against human, mouse, and rat plasma DPP-IV, respectively. RBx-0597 shows potential for type 2 diabetes research.
    RBx-0597
  • HY-117985BS
    Evogliptin-d9 tartrate
    Inhibitor
    Evogliptin-d9 tartrate (DA-1229-d9 tartrate) is the deuterium labeled Evogliptin tartrate (HY-117985B). Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation.
    Evogliptin-d<sub>9</sub> tartrate
  • HY-15695R
    Puromycin aminonucleoside (Standard)
    Inhibitor
    Puromycin aminonucleoside (Standard) is the analytical standard of Puromycin aminonucleoside. This product is intended for research and analytical applications. Puromycin aminonucleoside (NSC 3056) is the aminonucleoside portion of the antibiotic puromycin, and used in nephrosis animal models[1]. Puromycin aminonucleoside induces apoptosis[2]. Puromycin aminonucleoside is a reversible inhibitor of dipeptidyl peptidase II and cytosol alanyl aminopeptidase[3]. Puromycin aminonucleoside induces secretion of cell migrasome[4].
    Puromycin aminonucleoside (Standard)
  • HY-184139
    KGDI-109
    Inhibitor
    KGDI-109 is an orally active and selective Porphyromonas gingivalis dipeptidyl peptidase 7 (PgDPP7) inhibitor with an IC50 of 53.8 µM and a Ki of 25.1 µM. KGDI-109 is also a selective antibacterial agent that suppresses Porphyromonas gingivalis growth, reduces oral Porphyromonas gingivalis levels, and suppresses alveolar bone resorption. KGDI-109 preserves gut microbial diversity. KGDI-109 can be used for the research of periodontitis.
    KGDI-109
  • HY-14291S1
    Vildagliptin-d7
    Inhibitor
    Vildagliptin-d7 is deuterium labeled Vildagliptin. Vildagliptin (LAF237) is a potent, stable, selective dipeptidyl peptidase IV (DPP-IV) inhibitor with an IC50 of 3.5 nM in human Caco-2 cells. Vildagliptin possesses excellent oral bioavailability and potent antihyperglycemic activity.
    Vildagliptin-d<sub>7</sub>
  • HY-155961
    Antidiabetic agent 2
    Inhibitor
    Antidiabetic agent 2 (Compound 56) is a glucose-uptake promoter. Antidiabetic agent 2 inhibits DPP-4, PTP-1B, α-amylase, and α-glucosidase with IC50s of 0.036, 0.042, 0.241, 0.185 μM. Antidiabetic agent 2 decreases blood glucose levels.
    Antidiabetic agent 2
  • HY-111294
    ASP4000 hydrochloride
    Inhibitor
    ASP4000 hydrochloride is a potent, competitive, selective, orally active DPP4 inhibitor with an IC50 value of 2.25 nM against human recombinant DPP4. ASP4000 hydrochloride shows antihyperglycemic activity. ASP4000 hydrochloride can be used in the research of type 2 diabetes.
    ASP4000 hydrochloride
  • HY-168621
    DPP-4-IN-13
    Inhibitor
    DPP-4-IN-13 (compound 9i) is a competitive DPP4 inhibitor with the IC50 of 9.25 μM and can be used for study of type 2 diabetes.
    DPP-4-IN-13
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.